CL2020002598A1 - Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida - Google Patents

Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida

Info

Publication number
CL2020002598A1
CL2020002598A1 CL2020002598A CL2020002598A CL2020002598A1 CL 2020002598 A1 CL2020002598 A1 CL 2020002598A1 CL 2020002598 A CL2020002598 A CL 2020002598A CL 2020002598 A CL2020002598 A CL 2020002598A CL 2020002598 A1 CL2020002598 A1 CL 2020002598A1
Authority
CL
Chile
Prior art keywords
preparation
triazolone
trisubstituted
compound
intermediates
Prior art date
Application number
CL2020002598A
Other languages
English (en)
Inventor
Hassfeld Jorma
Nikolaus Gradl Stefan
Rubenbauer Philipp
Nicolaas Sebastiaan Van Der Haas Henricus
Gerardus Gieling Reinerus
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CL2020002598A1 publication Critical patent/CL2020002598A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona métodos para la preparación del Compuesto (I), el uso de compuestos intermedios para la preparación de dicho compuesto y su forma cristalina A.
CL2020002598A 2018-04-10 2020-10-08 Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida CL2020002598A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166552 2018-04-10
EP18212916 2018-12-17

Publications (1)

Publication Number Publication Date
CL2020002598A1 true CL2020002598A1 (es) 2020-12-04

Family

ID=66001239

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002598A CL2020002598A1 (es) 2018-04-10 2020-10-08 Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida

Country Status (17)

Country Link
US (1) US11365179B2 (es)
EP (1) EP3774786B1 (es)
JP (1) JP7476107B2 (es)
KR (1) KR20200141066A (es)
CN (1) CN112236426B (es)
AU (1) AU2019251694A1 (es)
BR (1) BR112020020596A2 (es)
CA (1) CA3096477A1 (es)
CL (1) CL2020002598A1 (es)
CO (1) CO2020012574A2 (es)
IL (1) IL277860A (es)
JO (1) JOP20200256A1 (es)
MX (1) MX2020010655A (es)
PE (1) PE20210159A1 (es)
SG (1) SG11202009943QA (es)
TW (1) TW201945346A (es)
WO (1) WO2019197239A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018077944A2 (en) * 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2022012548A1 (en) * 2020-07-14 2022-01-20 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
CN116444525B (zh) * 2023-03-27 2024-11-12 四川青木制药有限公司 一种盐酸泊那替尼a晶型的制备方法
EP4714438A1 (en) * 2024-09-20 2026-03-25 UMC Utrecht Holding B.V. Use of dhodh inhibitors in treatment of a smarcb1 mutant associated cancer
WO2026062223A1 (en) * 2024-09-20 2026-03-26 Prinses Máxima Centrum Voor Kinderoncologie B.V. Use of dhodh-inhibitors for the treatment of cmarcb1 -mutant associated cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2156472A1 (de) 1970-11-23 1972-05-31 Ciba-Geigy Ag, Basel (Schweiz) Verfahren zur Herstellung von neuen Diazepinderivaten
US4089958A (en) 1976-12-20 1978-05-16 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2]quinoxalin-5(6)-ones and derivatives thereof
CA2109524A1 (en) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
AR022889A1 (es) 1999-03-12 2002-09-04 Bayer Cropscience Ag Agente desfoliante
KR20100124262A (ko) * 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
MX2011006084A (es) 2008-12-08 2011-09-06 Sirtris Pharmaceuticals Inc Isoindolinona y analogos relacionados como moduladores de sirtuina.
JP5868575B2 (ja) 2010-04-15 2016-02-24 浜松ホトニクス株式会社 接続基板
CN103006645A (zh) 2011-09-27 2013-04-03 华东理工大学 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA2892919A1 (en) 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
WO2018077944A2 (en) 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)

Also Published As

Publication number Publication date
CN112236426A (zh) 2021-01-15
US11365179B2 (en) 2022-06-21
AU2019251694A1 (en) 2020-10-22
WO2019197239A1 (en) 2019-10-17
KR20200141066A (ko) 2020-12-17
CO2020012574A2 (es) 2020-10-30
PE20210159A1 (es) 2021-01-26
CA3096477A1 (en) 2019-10-17
JP2021521166A (ja) 2021-08-26
MX2020010655A (es) 2020-10-28
US20210032212A1 (en) 2021-02-04
TW201945346A (zh) 2019-12-01
BR112020020596A2 (pt) 2021-01-12
SG11202009943QA (en) 2020-11-27
JP7476107B2 (ja) 2024-04-30
IL277860A (en) 2020-11-30
JOP20200256A1 (ar) 2020-10-08
EP3774786B1 (en) 2024-12-25
CN112236426B (zh) 2024-07-05
EP3774786A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
CO2020012574A2 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2022003401A (es) Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
UY36730A (es) Fenoxifenilamidinas sustituidas con halógeno y el uso de estas como fungicidas
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
AR112276A1 (es) Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX384201B (es) Proceso para la preparacion de treprostinil.
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
UY36781A (es) Fenoxihalogenofenilamidinas y su uso como fungicidas
MX2017006224A (es) Derivados heterociclicos y usos de los mismos.
BR112019023123A2 (pt) Artigo pultrudado, uso do artigo pultrudado, método para formar o artigo
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
AR110768A1 (es) Formas cristalinas de tenofovir alafenamida
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
CO2020007895A2 (es) Inhibidores de histona acetiltransferasa de la familia myst
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
PT3908584T (pt) Formas cristalinas de 1-(1,2-dimetilpropil)-n-etil-5- metil-n-piridazin-4-il-pirazol-4-carboxamida
UY40794A (es) Formas cristalinas de (s)-afoxolaner
CL2019001804A1 (es) Activador de nrf2.
CO2020006206A2 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
CL2020000217A1 (es) Inhibidores de ror gamma.